Full Press Release Details
Corporation Reports First Quarter 2020 Financial Results and Provides Business Update
III OPTIMA Study on Track for Interim Data Analysis in July
Call Begins Today at 11:00 a.m. Eastern Time
N.J. (May 15, 2020) - Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced
financial results for the three months ended March 31, 2020, and provided an update on clinical development programs with ThermoDox ,
its proprietary heat-activated liposomal encapsulation of doxorubicin currently in Phase III development for the treatment of
hepatocellular carcinoma (HCC), or primary liver cancer, and GEN-1, its DNA-mediated IL-12 immunotherapy, currently in Phase I/II
development for the treatment of advanced stage ovarian cancer.
the first quarter and recent weeks, Celsion continued to make substantial progress with our ongoing development programs with
ThermoDox and GEN-1, while maintaining a strong balance sheet," said Michael H. Tardugno, Celsion's chairman,
president and chief executive officer. "With our pivotal 556-patient Phase III OPTIMA Study in HCC fully enrolled, we now
look forward to the preplanned interim efficacy analysis in July 2020."
GEN-1 immunotherapy product continued to show encouraging results at the 100 mg/m² dose cohort in the OVATION 2 Study, which
is consistent with the results reported from our earlier Phase Ib trial (the OVATION 1 Study) in advanced stage ovarian cancer.
These findings were reinforced by strong progression-free survival when comparing study patients to a statistically validated
synthetic control arm of matched patients from prior studies. This unique means of evaluating efficacy holds great potential for
clinical research, and we plan to use it in upcoming discussions with the U.S. Food and Drug Administration as part of our goal
to accelerate GEN-1 clinical development. In addition, GEN-1 received Orphan Drug Designation from the European Medicines Agency
in April 2020." Mr. Tardugno added, "Our fundamentals are strong, and we are well positioned with a capital structure
sufficient to see our clinical programs through transformative milestones in 2020."
Number of Patient Deaths Were Reached for the Second Interim Analysis of the Phase III OPTIMA Study of ThermoDox in Primary
Liver Cancer. In April 2020 the Company announced that the prescribed minimum number of events (158 patient deaths) was
reached for the second pre-specified interim analysis of the OPTIMA Phase III Study with ThermoDox plus RFA (radiofrequency
ablation) in patients with HCC. Following preparation of the data, the Independent Data Monitoring Committee (iDMC) is expected
to meet in July to conduct the second interim analysis. Celsion expects to announce iDMC recommendations as soon as possible after
the meeting. The hazard ratio (HR) and p-value necessary for success at 158 deaths are 0.70 and 0.022, respectively, which compare
favorably with the hazard ratio and p-value observed in the prospective HEAT Study subgroup upon which the OPTIMA Study is based.
OPTIMA Study was fully enrolled in August 2018 with 556 subjects from 65 clinical sites in 14 countries. The study design is based
on the Company's HEAT Study, in which a prospective subgroup analysis of 285 subjects with a single lesion of 3-7 cm in
size received a single ThermoDox administration in combination with a 45 minute or longer RFA procedure. Followed
prospectively for 3 years, those patients demonstrated a median survival of more than 7 ½ years and a survival benefit
of more than 2 years over the control group. These data were published in the October 2017 issue of the peer-reviewed journal
Clinical Cancer Research, and are available here.
Showed Strong Progression-Free Survival Treatment Effect Utilizing Medidata's Synthetic Control Arm. In
March 2020 the Company announced that Medidata-matched patient data from a synthetic control arm (SCA) compared with results from
the Company's completed Phase Ib dose-escalating OVATION 1 Study with GEN-1 in Stage III/IV ovarian cancer patients showed
positive results in progression-free survival (PFS). The HR was 0.53 in the intent-to-treat group, showing strong signals of efficacy.
Medidata is a globally recognized leader in clinical data management.
believes these data may warrant consideration of strategies to accelerate the clinical development for GEN-1 in newly diagnosed,
advanced ovarian cancer patients by the U.S. Food and Drug Administration (FDA). In its March 2019 discussion with Celsion, the
FDA noted that preliminary findings from the Phase Ib OVATION 1 Study were exciting but lacked a control group to evaluate GEN-1's
independent impact on impressive tumor response, surgical results and PFS. The FDA encouraged Celsion to continue its GEN-1 development
program and consult with FDA with new findings that may have a bearing on designations such as Fast Track and Breakthrough Therapy.
strong and encouraging treatment effect, evidenced by the synthetic control arm, suggests a potentially remarkable improvement
in PFS, an FDA-recognized surrogate for overall survival, and appears to confirm the science behind IL-12's ability to recruit
the innate and adaptive elements of the immune system to fight malignancies. The strong PFS trend is supported by previously published
translational data that clearly demonstrate the pro-immune changes in the tumor micro-environment associated with loco-regional
GEN-1 therapy. Celsion's randomized Phase II OVATION 2 Study in advanced ovarian cancer patients is expected to commence
in the fourth quarter of 2020 and is designed to demonstrate a 33% improvement in PFS (HR = 0.75) over current standard of care.
PFS is the primary endpoint for this study.
have the potential to revolutionize clinical trials in certain oncology indications and some other diseases where a randomized
control is not ethical or practical. SCAs are formed by carefully selecting control patients from historical clinical trials to
match the demographic and disease characteristics of the patients treated with the new investigational product. SCAs have been
shown to mimic the results of traditional randomized controls so that the treatment effects of an investigational product can
be visible by comparison to the SCA. SCAs can help advance the scientific validity of single-arm trials, and in certain indications,
reduce time and cost, and expose fewer patients to placebos or existing standard-of-care treatments that might not be effective
for them. Medidata is in a unique position to create fit-for-purpose synthetic controls because of access to a pool of more than
six million anonymized patients from nearly 20,000 previous clinical trials.
data generated from this analysis comparing GEN-1 with SCA showed the following:
| GEN-1 Population | PFS Hazard Ratio (Confidence Interval) | |
| Intent-to-treat, n=15 | 0.53 (95% CI 0.16, 1.73); log-rank p=0.29 | |
| Per-protocol, n=14 | 0.33 (95% CI 0.08, 1.37); log-rank p=0.11 |
Encouraging Initial Clinical Results from the Phase I Portion of the Phase I/II OVATION 2 Study with GEN-1 in Patients with Advanced
Ovarian Cancer. In March 2020 the Company announced highly encouraging initial clinical data from the first 15 patients
enrolled in the ongoing Phase I/II OVATION 2 Study for patients newly diagnosed with Stage III and IV ovarian cancer. The OVATION
2 Study combines GEN-1, the Company's IL-12 gene-mediated immunotherapy, with standard-of-care neoadjuvant chemotherapy
(NACT). Following NACT, patients undergo interval debulking surgery (IDS), followed by three additional cycles of chemotherapy.
plus standard NACT produced positive dose-dependent efficacy results, with no dose-limiting toxicities, which correlates well
with successful surgical outcomes as summarized below:
| Of the 15 patients treated in the Phase I portion of the OVATION 2 Study, nine were treated with GEN-1 at a dose of 100 mg/m² plus NACT and six were treated with NACT only. All 15 had successful resections of their tumors, with seven out of nine patients (78%) in the GEN-1 treatment arm having an R0 resection, which indicates a microscopically margin-negative resection in which no gross or microscopic tumor remains in the tumor bed. Only three out of six patients (50%) in the NACT only treatment arm had an R0 resection. | ||
| When combining these results with the surgical resection rates observed in the Company's prior Phase Ib dose-escalation trial (the OVATION 1 Study), a population of patients with inclusion criteria identical to the OVATION 2 Study, the data reflect the strong dose-dependent efficacy of adding GEN-1 to the current standard of care NACT: |
| % of Patients with | ||||||||
| R0 Resections | ||||||||
| 0, 36, 47 mg/m² of GEN-1 plus NACT | n=12 | 42 | % | |||||
| 61, 79, 100 mg/m² of GEN-1 plus NACT | n=17 | 82 | % |
Received Orphan Drug Designation from the European Medicines Agency. In March 2020 the Company announced the European
Medicines Agency (EMA) Committee for Orphan Medicinal Products recommended that GEN-1 be designated as an orphan medicinal product
for the treatment of ovarian cancer. As established by the EMA, this designation provides for scientific advice and certain regulatory
assistance during the product development phase, direct access to centralized marketing authorization and certain financial incentives
for companies developing new therapies intended for the treatment of a life-threatening or chronically debilitating condition
that affects no more than five in 10,000 people in the European Union (EU).
of the designation include:
| 10 years of market exclusivity (in which other industry sponsors are prevented from entering the market with a similar product for the same therapeutic indication); | ||
| EMA protocol assistance for sponsors on the conduct of the tests and trials necessary to demonstrate their quality, safety and efficacy, or regulatory assistance; | ||
| EMA advice will be free or given in return for reduced fees; | ||
| Access to a centralized procedure allowing immediate marketing authorization in all Member States and facilitating the availability of medicines to all patients in the EU; | ||
| Eligibility for a reduction of regulatory fees associated with pre-authorization inspections, as well as marketing authorization application fees and certain other fees for qualifying companies. |
previously received orphan drug designation from the FDA.
$1.8 Million in Non-Dilutive Funding from the Sale of Its New Jersey State Net Operating Losses. In April 2020 the Company
announced it received $1.82 million of
net cash proceeds from the sale of approximately $1.9 million of its unused New
Jersey net operating losses (NOLs). The NOL sales cover the tax years 2017 and 2018 and
are administered through the New Jersey Economic Development Authority's (NJEDA) Technology Business Tax Certificate Transfer
(NOL) Program. With this new non-dilutive funding, coupled with the $4.4 million in
net proceeds from the recent registered direct equity offer completed on March 3, 2020,
the Company strengthened its balance sheet at a time of capital markets uncertainty. An additional sale of $2.0 million
of unused New Jersey NOLs anticipated in the second half of 2020 will further increase Celsion's
cash reserves on a non-dilutive basis. In addition, the Company initiated several cost containment measures to ensure that it
has sufficient cash to fund operations and clinical development programs through the second quarter of 2021, which includes all
major Phase III OPTIMA Study readouts.
April 21, 2020, we entered into a loan agreement with Silicon Valley Bank (the "PPP Loan"), pursuant to the Paycheck
Protection Program of the Coronavirus Aid, Relief, and Economic Security Act. We thereafter received proceeds of $632,220 under
the PPP Loan. The PPP Loan application required Celsion to certify that there was economic uncertainty surrounding the Company
and that, as such, the PPP Loan was necessary to support our ongoing operations. Celsion made this certification in good faith
after analyzing, among other things, its financial situation and access to alternative forms of capital, and believes that the
Company satisfied all eligibility criteria for the PPP Loan, and that our receipt of the PPP Loan proceeds was consistent with
the broad objectives of the PPP of the CARES Act. The certification given with respect to the PPP Loan does not contain any objective
criteria and is subject to interpretation. In light of subsequent guidance issued by the U.S. Small Business Administration in
consultation with the U.S. Department of the Treasury, out of an abundance of caution, we returned the proceeds of the PPP Loan
in full on May 13, 2020. Celsion may choose to reapply for the loan if the SBA provides future applicable guidance.